MEK inhibitors: A therapeutic approach to targeting the Ras-MAP kinase pathway in tumors

Current Pharmaceutical Design

Volumn 10, Issue 16, 2004, Pages 1907-1914

  Sebolt Leopold, Judith S ^a  

^a PFIZER INC   (United States)

Author keywords

CI 1040 and tumor; ERK; MAP kinase; MEK inhibitor; MEK1; MEK2

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 (2 CHLORO 4 IODOANILINO) N CYCLOPROPYLMETHOXY 3,4 DIFLUOROBENZAMIDE; ANTINEOPLASTIC AGENT; CELL RECEPTOR; GROWTH FACTOR; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; RAF PROTEIN; RAS PROTEIN; SERINE; VITRONECTIN RECEPTOR;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BIOCHEMISTRY; CELL ACTIVITY; CELL GROWTH; CELL PROLIFERATION; CELL SURVIVAL; CLINICAL TRIAL; COLON CARCINOMA; DIARRHEA; DRUG ERUPTION; DRUG TARGETING; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME SPECIFICITY; FATIGUE; GROWTH INHIBITION; HUMAN; IN VIVO STUDY; INHIBITION KINETICS; LEUKEMIA CELL; MAJOR CLINICAL STUDY; MALIGNANT NEOPLASTIC DISEASE; METASTASIS INHIBITION; METHODOLOGY; MOUSE; NAUSEA AND VOMITING; NONHUMAN; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN INTERACTION; PROTEIN PHOSPHORYLATION; RECEPTOR BINDING; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; STIMULUS RESPONSE; TREATMENT OUTCOME; TUMOR CELL;

ANIMALS; DRUG DELIVERY SYSTEMS; ENZYME INHIBITORS; HUMANS; MAP KINASE KINASE KINASES; MAP KINASE SIGNALING SYSTEM; NEOPLASMS; RAS PROTEINS;

EID: 2442615800     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/1381612043384439     Document Type: Review

References (99)

1. Anderson NG, Maller JL, Tonks NK, Sturgill TW. Requirement for integration of signals from two distinct phosphorylation pathways for activation of MAP kinase. Nature 1990; 343: 651-3.
2. Seger R, Ahn NG, Posada J, Munar ES, Jensen AM, Cooper JA, et al. Purification and characterization of mitogen-activated protein kinase activator(s) from epidermal growth factor-stimulated A431 cells. J Biol Chem 1992; 267: 14373-81.
3. Warne PH, Viciana PR, Downward J. Direct interaction of Ras and the amino-terminal region of Raf-1 in vitro. Nature 1993; 364: 352-5.
4. Dent P, Haser W, Haystead TA, Vincent LA, Roberts TM, Sturgill TW. Activation of mitogen activated protein kinase kinase by v-Raf in NIH 3T3 cells and in vitro. Science 1992; 257: 1404-7.
5. Robinson MJ, Cobb MH. Mitogen-activated protein kinase pathway. Curr Opin Cell Biol 1997; 9: 180-6.
6. Seger R, Krebs EG. The MAPK signaling cascade. FASEB J 1995; 9: 726-35.
7. Cobb MH, Goldsmith EJ. How MAP kinases are regulated. J. Biol Chem 1995; 270: 14843-6.
8. Lewis TS, Shapiro PS, Ahn NG. Signal transduction through MAP kinase cascades. Adv Cancer Res 1998; 74: 49-139.
9. Marshall CJ. Specificity of receptor tyrosine kinase signaling: transient versus sustained extracellular signal-regulated kinase activation. Cell 1995; 80: 179-85.
10. Schaeffer HJ, Weber MJ. Mitogen-activated protein kinases: specific messages from ubiquitous messengers. Mol Cell Biol 1999; 19: 2435-44.
11. Dhanasekaran N, Premkumar Reddy E. Signaling by dual specificity kinases. Oncogene 1998; 17: 1447-55.
12. McCormick F. Signal transduction. How receptors turn Ras on. Nature 1993; 363: 15-16.
13. Sasaoka T, Langlois WJ, Leitner JW, Draznin B, Olefsky JM. The signaling pathway coupling epidermal growth factor receptors to activation of p21ras. J Biol Chem 1994; 269: 32621-5.
14. Hunter T. Protein kinases and phosphatases: The yin and yang of protein phosphorylation and signaling. Cell 1995; 80: 225-36.
15. Buday L, Downward J. Epidermal growth factor regulates p21ras through the formation of a complex of receptor, Grb2 adapter protein, and Sos nucleotide exchange factor. Cell 1993; 73: 611-20.
16. Daum G, Eisenmann-Tappe I, Fries HW, Troppmair J, Rapp UR. The ins and outs of Raf kinases. Trends Biochem Sci 1994; 19: 474-80.
17. Hill CS, Treisman R. Transcriptional regulation by extracellular signals: mechanisms and specificity. Cell 1995; 80: 199-211.
18. Timms JF, White SL, O'Hare MJ, Waterfield MD. Effects of ErbB-2 overexpression on mitogenic signaling and cell cycle progression in human breast luminal epithelial cells. Oncogene 2002; 21: 6573-86.
19. Zwick E, Bange J, Ullrich A. Receptor tyrosine kinases as targets for anticancer drugs. Trends Mol Med 2002; 8: 17-23.
20. Cowley S, Paterson H, Kemp P, Marshall CJ. Activation of MAP kinase kinase is necessary and sufficient for PC12 differentiation and for transformation of NIH 3T3 cells. Cell 1994; 77: 841-852.
21. Mansour SJ, Matten WT, Hermann AS, Candia JM, Rong S, Fukasawa K, et al. Transformation of mammalian cells by constitutively active MAP kinase kinase. Science 1994; 265: 966-70.
22. Sivaraman VS, Wang H, Nuovo GJ, Malbon CC. Hyperexpression of mitogen-activated protein kinase in human breast cancer. J Clin Invest 1997; 99: 1478-83.
23. Mandell JW, Hussaini IM, Zecevic M, Weber MJ, VandenBerg SR. In situ visualization of intratumor growth factor signaling: immunohistochemical localization of activated ERK/MAP kinase in glial neoplasms. Am J Pathol 1998; 153: 1411-23.
24. Hoshino R, Chatani Y, Yamori T, Tsuruo T, Oka H, Yoshida O, et al. Constitutive activation of the 41-/43-dDa mitogen-activated protein kinase signaling pathway in human tumors. Oncogene 1999; 18: 813-22.
25. Das R, Vonderhaar BK. Activation of raf-1, MEK, and MAP kinase in prolactin responsive mammary cells. Breast Cancer Res Treat 1996; 40: 141-9.
26. Janes PW, Daly RJ, deFazio A, Sutherland RL. Activation of the Ras signaling pathway in human breast cancer cells overexpressing erbB-2. Oncogene 1994; 9: 3601-8.
27. Fiddes, RJ, Janes PW, Siversten SP, Sutherland RL, Musgrove EA, Daly RJ. Inhibition of the MAP kinase cascade blocks heregulin-induced cell cycle progression in T-47D human breast cancer cells. Oncogene 1998; 16: 2803-13.
28. Kannan S, De Santis M, Lohmeyer M, Riese DJ 2nd, Smith GH, Hynes N, et al. Cripto enhances the tyrosine phosphorylation of Shc and activates mitogen-activated protein kinase (MAPK) in mammary epithelial cells. J Biol Chem 1997; 272: 3330-5.
29. von Lintig FC, Dreilinger AD, Varki NM, Wallace AM, Casteel DE, Boss GR. Ras activation in human breast cancer. Breast Cancer Res Treat 2000; 62: 51-62.
30. Kato S, Endoh H, Masuhiro Y, Kitamoto T, Uchiyama S, Sasaki H, et al. Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science 1995; 270: 1491-4.
31. Maemura M, Iino Y, Koibuchi Y, Yokoe T, Morishita Y. Mitogen-activated protein kinase cascade in breast cancer. Oncology 1999; 57: 37-44 (suppl 2)
32. Mueller H, Flury N, Eppenberger-Castori S, Kueng W, David F, Eppenberger U. Potential prognostic value of mitogen-activated protein kinase activity for disease-free survival of primary breast cancer patients. Int J Cancer 2000; 89: 384-8.
33. Donovan JC, Milic A, Slingerland JM. Constitutive MEK/MAPK activation leads to p27(Kip1) deregulation and antiestrogen resistance in human breast cancer cells. J Biol Chem 2001; 276: 40888-95.
34. Coutts AS, Murphy LC. Elevated mitogen-activated protein kinase activity in estrogen-nonresponsive human breast cancer cells. Cancer Res 1998; 58: 4071-4.
35. El-Ashry D, Mille DL, Kharbanda S, Lippman ME, Kern FG. Constitutive Raf-1 kinase activity in breast cancer cells induces both estrogen-independent growth and apoptosis. Oncogene 1997; 15: 423-35.
36. Manzano RG, Montuenga LM, Dayton M, Dent P, Kinoshita I, Vicent, et al. CL100 expression is down-regulated in advanced epithelial ovarian cancer and its re-expression decreases its malignant potential. Oncogene 2002; 21: 4435-47.
37. Gioeli D, Mandell JW, Petroni GR, Frierson Jr, HF, Weber MJ. Activation of mitogen-activated protein kinase associated with prostate cancer progression. Cancer Res 1999; 59: 279-84.
38. Downward J. Targeting Ras signaling pathways in cancer therapy. Nature Reviews/Cancer 2003; 3: 11-22.
39. Brott, BK, Alessandrini, A, Largaespada, DA, Copeland, NG, Jenkins, NA, Crews, CM, Erikson, RL. MEK2 is a kinase related to MEK1 and is differentially expressed in murine tissues. Cell Growth Differ 1993; 4: 921-9.
40. Haystead TA, Dent P, Wu J, Haystead CM, Sturgill TW. Ordered phosphorylation of p42mapk by MAP kinase kinase. FEBS Lett 1992; 306: 17-22.
41. Zheng, CF, Guan, KL. Properties of MEKs, the kinases that phosphorylate and activate the extracellular signal-regulated kinases. J Biol Chem 1993; 268: 23933-9.
42. Schaeffer HJ, Catling AD, Eblen ST, Collier LS, Krauss A, Weber MJ. MP1: a MEK binding partner that enhances enzymatic activation of the MAP kinase cascade. Science 1998; 281: 1668-71.
43. Jelinek T, Catling AD, Reuter CW, Moodie SA, Wolfman A, Weber MJ. RAS and RAF-1 form a signaling complex with MEK-1 but not MEK-2. Mol Cell Biol 1994; 14: 8212-8.
44. Catling AD, Schaeffer HJ, Reuter CW, Reddy GR, Weber MJ. A proline-rich sequence unique to MEK1 and MEK2 is required for Raf binding and regulates MEK function. Mol Cell Biol 1995; 15: 5214-25.
45. Wu X, Noh SJ, Zhou G, Dixon JE, Guan KL. Selective activation of MEK1 but not MEK2 by A-Raf from epidermal growth factor-stimulated Hela cells. J Biol Chem 1996; 271: 3265-71.
46. Giroux S, Gtremblay M, Bernard D, Cadrin-Girard JF, Aubry S, Larouche L, et al. Embryonic death of Mek1-deficient mice reveals a role for this kinase in angiogenesis in the labyrinthine region of the placenta. Current Biol 1999; 9: 369-72.
47. Belanger LF, Roy S, Tremblay M, Brott B, Steff AM, Mourad W, et al. Mek2 is dispensable for mouse growth and development. Mol Cell Biol 2003; 23: 4778-87.
48. Crews CM, Alessandrini A, Erikson RE. The primary structure of MEK, a protein kinase that phosphorylates the ERK gene product. Science 1992; 258: 478-80.
49. Coles LC, Shaw PE. PAK1 primes MEK1 for phosphorylation by Raf-1 kinase during cross-cascade activation of the ERK pathway. Oncogene 2002; 28: 2236-44.
50. Eblen ST, Slack JK, Weber MJ, Catling AD. Rac-PAK signaling stimulates extracellular signal-regulated kinase (ERK) activation by regulating formation of MEK1-ERK complexes. Mol Cell Biol 2002; 22: 6023-33.
51. Sebolt-Leopold JS. Development of anticancer drugs targeting the MAP kinase pathway. Oncogene 2000; 19: 6594-9.
52. Herrera R, Sebolt-Leopold JS. Unraveling the complexities of the Raf/MAP kinase pathway for pharmacological intervention. TRENDS Guide to Cancer Therapeutics 2002; S27-S31.
53. English JM, Cobb MH. Pharmacological inhibitors of MAPK pathways. Trends in Pharmacological Sciences 2002; 23: 40-5.
54. Dudley Df, Pang L, Decker SJ, Bridges AJ, Saltiel AR. A synthetic inhibitor of the mitogen-activated protein kinase cascade. Proc Natl Acad Sci USA 1995; 92: 7686-9.
55. Alessi DR, Cuenda A, Cohen P, Dudley DT, Saltiel AR. PD098059 is a specific inhibitor of the activation of mitogen-activated protein kinase kinase in vitro and in vivo. J Biol Chem 1995; 270: 27489-94.
56. Favata MF, Horiuchi KY, Manos EJ, Daulerio AJ, Stradley DA, Feceser WS, et al. Identification of a novel inhibitor of mitogen-activated protein kinase kinase. J Biol Chem 1998; 273: 18623-32.
57. Ahn NG, Nahreini TS, Tolwinski NS, Resing KA. Pharmacological inhibitors of MKK1 and MKK2. Methods Enzymol 2001; 332: 417-31.
58. Davies SP, Reddy H, Caivano M, Cohen P. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J 2000; 351: 95-105.
59. Zhang N, Wu B, Powell D, Wissner A, Floyd MB, Kovacs ED, et al. Synthesis and structure-activity relationships of 3-cyano-4-(phenoxyanilino)quinolines as MEK (MAPKK) inhibitors. Bioorg Med Chem Lett 2000; 10: 2825-8.
60. Sebolt-Leopold JS, Dudley DT, Herrera R, Van Becelaere K, Wiland A, Gowan RC, et al. Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo. Nature Med 1999; 5: 810-6.
61. Pouyssegur J, Volmat V, Lenormand P. Fidelity and spatio-temporal control in MAP kinase (ERKs) signaling, Biochem Pharmacol 2002; 64: 755-63.
62. Yordy JS, Muise-Helmericks RC. Signal transduction and the Ets family of transcription factors. Oncogene 2000; 19: 6503-13.
63. Pruitt K, Der CJ. Ras and Rho regulation of the cell cycle and oncogenesis. Cancer Lett 2001; 171: 1-10.
64. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2001; 100: 57-70.
65. Talapatra S, Thompson C B. Growth factor signaling in cell survival: implications for cancer treatment. J Pharmacol Exp Ther 2001; 298: 873-8.
66. Weinstein-Oppenheimer CR, Blalock WE, Steelman LS, Chang F, McCubrey JA. The Raf signal transduction cascade as a target for chemotherapeutic intervention in growth factor-responsive tumors. Pharmacol Ther 2000; 88: 229-79.
67. Lau QC, Brusselbach S, Muller R. Abrogation of c-Raf expression induces apoptosis in tumor cells. Oncogene 1998; 16: 1899-1902.
68. Ballif BA, Blenis J. Molecular mechanisms mediating mammalian mitogen-activated protein kinase (MAPK) kinase (MEK)-MAPK cell survival signals. Cell Growth Differ 2001; 12: 397-408.
69. Shimamura A, Ballif BA, Richards SA, Blenis J. Rsk1 mediates a MEK-MAP kinase cell survival signal. Curr Biol 2000; 10: 127-35.
70. Bonni A, Brunet A, West AE, Datta SR, Takasu MA, Greenberg ME. Cell survival promoted by the Ras-MAPK signaling pathway by transcription-dependent and -independent mechanisms. Science 1999; 286: 1358-62.
71. Murakami MS, Morrison DK. Raf-1 without MEK? Sci STKE 2001; 99: PE30
72. Wang HG, Miyashita T, Takayama S, Sato T, Torigoe T, Krajewski S, et al. Apoptosis regulation by interaction of Bcl-2 protein and Raf-1 kinase. Oncogene 1994; 9: 2751-6.
73. Zhong J, Troppmair J, Rapp UR. Independent control of cell survival by Raf-1 and Bcl-2 at the mitochondria. Oncogene 2001; 20: 4807-16.
74. Pearson G, Bumeister R, Henry DO, Cobb MH, White MA. Uncoupling Raf1 from MEK1/2 impairs only a subset of cellular responses to Raf activation. J Biol Chem 2000; 275: 37303-6.
75. Baumann B, Weber CK, Troppmair J, Whiteside S, Israel A, Rapp UR, et al. Raf induces NF-KB by membrane shuttle kinase MEKK1, a signaling pathway critical for transformation. Proc Natl Acad Sci USA 2000; 97: 4615-20.
76. Meng XW, Chandra J, Loegering D, Van Becelaere K, Kottke TJ, Gore,SD, et al. Central role of FADD in apoptosis induction by the mitogen activated protein kinase kinase inhibitor CI-1040 (PD184352) in acute lymphocytic leukemia cells in vitro. J Biol Chem 2003; in press.
77. Elliceiri BP, Klemke R, Stromblad S, Cheresh DA. Integrin alphavbeta3 requirement for sustained mitogen-activated protein kinase activity during angiogenesis. JCell Biol 1998; 140: 1255-63.
78. Milanini J, Vinals F, Pouyssegur J, Pages G. p42/p44 MAP kinase module plays a key role in the transcriptional regulation of the vascular endothelial growth factor gene in fibroblasts. J Biol Chem. 1998; 271: 18165-72.
79. Petit AM, Rak J, Hung MC, Rockwell P, Goldstein N, Fendly B, et al. Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors. Am J Pathol 1997; 151: 1523-30.
80. Sebolt-Leopold JS. AACR-NCI-EORTC International Conference in Miami Beach, Florida, 2001, p.167 (abstract #P818).
81. Zhu, WH, MacIntyre A, Nicosia, RF. Regulation of angiogenesis by vascular endothelial growth factor and angiopoietin-1 in the rat aorta model. Am J Pathol 2002; 161: 823-30.
82. Streit M, Schmidt R, Hilgenfeld RU, Thiel E, Kreuser ED. Adhesion receptors in malignant transformation and dissemination of gastrointestinal tumors. J Mol Med 1996; 74: 253-68.
83. Ridley AJ, Comoglio PM, Hall A. Regulation of scatter factor/hepatocyte growth factor responses by Ras, Rac and Rho in MDCK cells. Mol Cell Biol 1995; 15: 1110-22.
84. Herrera R. Modulation of hepatocyte growth factor-induced scattering of HT29 colon carcinoma cells. Involvement of the MAPK pathway. J Cell Science 1998; 111: 1039-49.
85. Potempa S, Ridley AJ. Activation of both MAP kinase and phosphatidylinositide 3-kinase by Ras is required for hepatocyte growth factor/scatter factor-induced adherens junction disassembly, Mol Biol Cell 1998; 9: 2185-200.
86. Tanimura S, Chatani Y, Hoshino R, Sato M, Watanabe S, Kataoka T, et al. Activation of the 41/43 kDa mitogen-activated protein kinase signaling pathway is required for hepatocyte growth factor-induced cell scattering. Oncogene 1998; 17: 57-65.
87. Webb CP, Van Aelst L, Wigler MH, Vande Woude GF. Signaling pathways in Ras-mediated tumorigenicity and metastasis. Proc Natl Acad Sci USA 1998; 95: 8773-8.
88. Pinkas J, Leder P. MEK1 signaling mediates transformation and ruetastasis of EpH4 mammary epithelial cells independent of an epithelial to mesenchymal transition. Cancer Res 2002; 62: 4781- 90.
89. Vial E, Sahai E, Marshall CJ. ERK-MAPK signaling coordinately regulates activity of Rac1 and RhoA for tumor cell motility. Cancer Cell 2003; 4: 67-79.
90. LoRusso P, Adjei A, Meyer M, Wozniak A, Gadgeel S, DeLuca P, et al. A phase 1 clinical and pharmacokinetic evaluation of the oral MEK inhibitor, CI-1040 administered for 21 consecutive days, repeated every 4 weeks in patients with advanced cancer. Proc Am Soc Clin Oncol 2002; 21: 81a (abstr 321).
91. Allen LF, Sebolt-Leopold JS, Meyer M. CI-1040 (PD184352), a targeted signal transduction inhibitor of MEK (MAPKK). Seminars in Oncology 2003; 30: in press.
92. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, et al. Mutations of the BRAF gene in human cancer. Nature 2002; 417: 949-54.
93. Brose MS, Volpe P, Feldman M, Kumar M, Rishi I, Gerrero R, et al. BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res 2002; 62: 6997-7000.
94. Kumar R, Angelini S, Czene K, Sauroja I, Hahka-Kemppinen M, Pyrhonen S, et al. BRAF mutations in metastatic melanoma: a possible association with clinical outcome. Clin Cancer Res 2003; 9: 3362-8.
95. Gorden A, Osman I, Gai W, He D, Huang W, Davidson A, et al. Analysis of BRAF and N-RAS mutations in netastatic melanoma tissues. Cancer Res 2003; 63: 3955-7.
96. Collisson EA, De A, Suzuki H, Gambhir S, Kolodney MS. Treatment of metastatic melanoma with an orally available inhibitor of the Ras-Raf-MAPK cascade. Cancer Res 2003; 63: 5669-73.
97. Dancey JE. Agents targeting ras signaling pathway. Curr Pharm Design 2002; 8(25): 2259-67.
98. Stewart JM. Bradykinin antagonists as anti-cancer agents. Curr Pharm Design 2003; 9(25): 2036-42.
99. Wilhelm S, Chien DS. BAY 43-9006: preclinical data. Curr Pharm Design 2002; 8(25): 2255-7.